Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2224518 | 0.75 | USP2 (0.47) | — | |
| SCHEMBL9852425 | 0.74 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL2634417 | 0.72 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL8915143 | 0.67 | — | — | |
| SCHEMBL9800446 | 0.66 | CTSK (0.31) | — | |
| SCHEMBL11310663 | 0.65 | — | — | |
| SCHEMBL12144120 | 0.63 | HRH3 (0.38) | — | |
| SCHEMBL28096491 | 0.63 | TSHR (0.52) | TSHR | |
| SCHEMBL7261429 | 0.62 | — | — | |
| SCHEMBL3424789 | 0.59 | ALDH1A1 (0.43) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20190322649-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2019-10-24 | — | — | US | disclosed |
| US-9546161-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyl transferase inhibitors | GENZYME CORPORATION (US) | 2017-01-17 | — | — | US | disclosed |
| US-8779163-B2 | Synthesis of UDP-Glucose: N-acylsphingosine glucosyl transferase inhibitors | GENZYME CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120296088-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYL TRANSFERASE INHIBITORS | GENZYME CORPORATION | 2012-11-22 | — | — | US | disclosed |
| US-7763738-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-7615573-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080058514-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | HIRTH BRADFORD H | 2008-03-06 | — | — | US | disclosed |
| US-7265228-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070203223-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2007-08-30 | — | — | US | disclosed |
| US-7196205-B2 | Synthesis of amino ceramide-like compounds; for treating Tay-Sachs, Gaucher's or Fabry's disease; amenable to large scale preparations | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050222244-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2005-10-06 | — | — | US | disclosed |
| US-6855830-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050009872-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| US-20030050299-A1 | An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents | GENZYME CORPORATION | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120296088-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYL TRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | TSHR 4390/4885 |
| US-20050222244-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGCG, UGGT1, DPAGT1 | TSHR 4491/4885 |
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | TSHR 4491/4885 |
| US-20080058514-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | TSHR 4491/4885 |
| US-20190322649-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | TSHR 4491/4885 |
| US-20050009872-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGCG, UGGT1, DPAGT1 | TSHR 4491/4885 |
| US-20070203223-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGCG, UGGT1, DPAGT1 | TSHR 4491/4885 |
| US-20030050299-A1 | An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents | UGCG, UGGT1, LCLAT1 | TSHR 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.